心血管疾患と診断

Imatinib-Induced Congestive Heart Failure: A Case Report

Abstract

Ahmed M Shafter

Imatinib has been approved by the FDA as an oral drug for the treatment of Chronic Myeloid Leukemia (CML), gastrointestinal stromal tumors (GISTs) and hyper eosinophilic syndrome. Although imatinib is well tolerated, the incidence of edema and dyspnea are reported to be as high as 66 and 16%, respectively. Imatinib-induced cardiotoxicity is a very uncommon adverse event <1%. A 53-year-old male with history of Chronic Myeloid Leukemia (CML) on Imatinib for the past 5 years. He presented with symptoms of exertional dyspnea, poor exercise performance, fatigue, and leg swellings. Chest X-ray revealed cardiomegaly, and pulmonary edema. Electrocardiogram showed normal sinus rhythm, no ischemic changes. Cardiac enzymes were normal. 2D Echocardiogram showed ejection fraction EF of 35%, normal pulmonary systolic pressure, no wall motion abnormality, with normal valvular function. In our case report, we discuss the association between Imatinib use and congestive heart failure, which may need discontinuing the medication and prompt treatment of congestive heart failure.